Syros Pharmaceuticals Inc (SYRS)
5.435
-0.04
(-0.82%)
USD |
NASDAQ |
May 17, 16:00
5.435
0.00 (0.00%)
After-Hours: 20:00
Syros Pharmaceuticals Enterprise Value: 78.74M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 78.74M |
| May 16, 2024 | 79.54M |
| May 15, 2024 | 80.34M |
| May 14, 2024 | 78.21M |
| May 13, 2024 | 68.32M |
| May 10, 2024 | 65.91M |
| May 09, 2024 | 66.98M |
| May 08, 2024 | 66.71M |
| May 07, 2024 | 70.72M |
| May 06, 2024 | 68.85M |
| May 03, 2024 | 70.19M |
| May 02, 2024 | 72.06M |
| May 01, 2024 | 78.47M |
| April 30, 2024 | 77.40M |
| April 29, 2024 | 76.87M |
| April 26, 2024 | 67.78M |
| April 25, 2024 | 69.39M |
| April 24, 2024 | 68.58M |
| April 23, 2024 | 70.45M |
| April 22, 2024 | 66.45M |
| April 19, 2024 | 54.42M |
| April 18, 2024 | 59.23M |
| April 17, 2024 | 69.65M |
| April 16, 2024 | 81.68M |
| April 15, 2024 | 76.07M |
| Date | Value |
|---|---|
| April 12, 2024 | 77.14M |
| April 11, 2024 | 91.30M |
| April 10, 2024 | 80.88M |
| April 09, 2024 | 80.08M |
| April 08, 2024 | 53.35M |
| April 05, 2024 | 57.89M |
| April 04, 2024 | 61.90M |
| April 03, 2024 | 66.18M |
| April 02, 2024 | 56.96M |
| April 01, 2024 | 67.78M |
| March 28, 2024 | 43.23M |
| March 27, 2024 | 56.19M |
| March 26, 2024 | 67.03M |
| March 25, 2024 | 71.00M |
| March 22, 2024 | 67.56M |
| March 21, 2024 | 69.41M |
| March 20, 2024 | 69.15M |
| March 19, 2024 | 66.50M |
| March 18, 2024 | 63.07M |
| March 15, 2024 | 60.68M |
| March 14, 2024 | 61.21M |
| March 13, 2024 | 72.85M |
| March 12, 2024 | 72.59M |
| March 11, 2024 | 75.23M |
| March 08, 2024 | 80.79M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-142.68M
Minimum
Dec 20 2022
749.35M
Maximum
Dec 23 2020
134.93M
Average
112.98M
Median
Nov 08 2019
Enterprise Value Benchmarks
| PAVmed Inc | 88.16M |
| Moderna Inc | 42.41B |
| Altimmune Inc | 385.90M |
| iBio Inc | 16.77M |
| Lixte Biotechnology Holdings Inc | 5.620M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.708M |
| Total Expenses (Quarterly) | 30.92M |
| EPS Diluted (Quarterly) | -0.10 |
| Earnings Yield | -92.66% |
| Normalized Earnings Yield | -81.68 |